CANNORDIC, the subsidiary of CS MEDICA, secures an exclusive deal with Deutsch-Pharm in Ukraine, signaling a sales potential of DKK 750.000.

CS MEDICA announces that its subsidiary, CANNORDIC, has established a white-label partnership with Deutsch-Pharm, a top pharmaceutical distributor in Ukraine. This deal is subject to successful product registration with Ukrainian health authorities and includes a 100% prepayment from Deutsch-Pharm upon registration approval, expected within a 1–2-month timeframe. The selected skin duo, comprising the Psoriasis Gel and Skin Relief Lotion, offers a comprehensive treatment solution. The gel is already compliant with the EU’s Medical Device Regulation (MDR), ensuring safety and effectiveness, while the cosmetic regulated skin lotion perfectly complements the treatment.

CS MEDICA prefers not to work with exclusivity; however, the grant of exclusive distribution rights to Deutsch-Pharm reflects CS MEDICA’s strategy to support its Ukrainian partner and maximize market entry.

Lone Henriksen, CEO of CS MEDICA, states, “Deutsch-Pharm visited us at CPHI in October, and we are pleased to have an agreement in place where we can enhance our footprint in the Eastern Europe market and especially demonstrate our commitment to supporting our customer as consumers under challenging conditions. While we have a three-year forecast in place, our immediate focus is on the swift launch of the first 20,000 units, utilizing the strength of our MDR-compliant skincare solution to expedite local registration and product availability”

Huzar Pavlo, General Manager for Deutsch-Pharm, comments: “We are happy for the exclusivity granted, which underscores the support and confidence CANNORDIC has in our operations during these challenging times. With Deutsch-Pharm’s robust distribution network and our commitment to delivering MDR-compliant products, we are poised to make an impact on the healthcare market. These unique products will allow us to effectively meet the growing demand for advanced skincare solutions and ensure that these innovative treatments are accessible to all Ukrainians.”

Deutsch-Pharm maintains a robust distribution network, with facilities in Kyiv, Dnipro, and Lviv, ensuring a localized market penetration and accessibility of CANNORDIC’s products throughout Ukraine.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

Deutsch-Pharm is one of Ukraine’s leading pharmaceutical distributors, renowned for its network and commitment to providing high-quality medical products across the country. Specializing in both prescription and over-the-counter medications, the company plays a critical role in ensuring access to reliable pharmaceutical solutions. With a strong emphasis on partnerships and expanding its portfolio, Deutsch-Pharm is poised for continued growth in the Ukrainian healthcare market. The company’s extensive distribution channels and strategic collaborations position it as a trusted leader in bringing innovative healthcare products to consumers and healthcare professionals alike.
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.